Targeting the ERK Signaling Pathway in Melanoma
Related Experiment Video
Updated: Jan 27, 2026

Photostimulation by Femtosecond Laser Activates Extracellular-signal-regulated Kinase ERK Signaling or Mitochondrial Events in Target Cells
Published on: July 6, 2019
Paola Savoia1, Paolo Fava2, Filippo Casoni3,4
1Department of Health Science, University of Eastern Piedmont, via Solaroli 17, 28100 Novara, Italy. paola.savoia@med.uniupo.it.
Abstract:
The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its progression have opened a new era in the treatment of this tumor. Vemurafenib was the first specific kinase inhibitor approved for therapy of advanced melanomas harboring BRAF-activating mutations, followed by dabrafenib and encorafenib. However, despite the excellent results of first-generation kinase inhibitors in terms of response rate, the average duration of the response was short, due to the onset of genetic and epigenetic resistance mechanisms. The combination therapy with MEK inhibitors is an excellent strategy to circumvent drug resistance, with the additional advantage of reducing side effects due to the paradoxical reactivation of the MAPK pathway. The recent development of RAS and extracellular signal-related kinases (ERK) inhibitors promises to add new players for the ultimate suppression of this signaling pathway and the control of pathway-related drug resistance. In this review, we analyze the pharmacological, preclinical, and clinical trial data of the various MAPK pathway inhibitors, with a keen interest for their clinical applicability in the management of advanced melanoma.
Insights
Targeting the RAS/RAF/MEK/ERK pathway with kinase inhibitors has revolutionized melanoma treatment. Combination therapies and new drug developments aim to overcome resistance and improve outcomes for advanced melanoma patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The RAS/RAF/MEK/ERK pathway is crucial in melanoma development and progression.
- BRAF inhibitors like vemurafenib, dabrafenib, and encorafenib have shown efficacy in advanced melanoma.
- Drug resistance limits the long-term effectiveness of first-generation BRAF inhibitors.
Purpose of the Study:
- To review the clinical applicability of MAPK pathway inhibitors in advanced melanoma.
- To analyze pharmacological, preclinical, and clinical data of various MAPK pathway inhibitors.
- To discuss strategies for overcoming drug resistance in melanoma treatment.
Main Methods:
- Review of pharmacological data.
- Analysis of preclinical study findings.
- Evaluation of clinical trial outcomes for MAPK pathway inhibitors.
Main Results:
- First-generation BRAF inhibitors offer high response rates but short durations due to resistance.
- Combination therapy with MEK inhibitors can circumvent resistance and reduce side effects.
- Emerging RAS and ERK inhibitors present new therapeutic avenues.
Conclusions:
- Targeting the MAPK pathway is a key strategy for advanced melanoma management.
- Combination therapies and novel inhibitors are essential for improving patient outcomes.
- Further research into clinical applicability of these inhibitors is warranted.
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway
Insulin: The Receptor and Signaling Pathways
IP3/DAG Signaling Pathway
Nitric Oxide Signaling Pathway

